Recent Updates — AZTR
Azitra has decided not to utilize its at-the-market offering (ATM) program for the foreseeable future. From September 28 through October 26, 2026, the company sold an aggregate of 1,000 shares under the ATM program for gross proceeds of approximately $126. Management cited current capital resources, anticipated operational milestones, recent trading price, and dilutive effects as reasons for suspending sales. The company may resume sales or pursue other financing transactions at its discretion. Azitra is a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high-value cosmetic proteins.
Azitra, Inc. filed a certificate of amendment to its Certificate of Incorporation with the State of Delaware to effectuate a one-for-ten reverse stock split of its common stock. The transaction becomes effective on October 26, 2026, at 12:01 a.m. Eastern Time, and shares are expected to begin trading on a split-adjusted basis on the NYSE American that same day. Stockholders entitled to fractional shares will receive cash in lieu thereof based on the average closing price over the five trading days preceding effectiveness. Azitra operates in the biopharmaceutical industry, focusing on drug discovery and development.
Azitra announced the completion of Cohort 1 in its Phase 1/2 clinical trial for ATR-04, a live biotherapeutic candidate targeting EGFR inhibitor-associated skin rash. Following a safety review by the study’s committee based on data from six patients, the company received clearance to proceed to Cohort 2. The trial is designed to evaluate the safety and tolerability of topical ATR-04 compared to its vehicle in adult patients. Azitra plans to enroll approximately 24 patients in Cohort 2, who will receive a once-daily 4g application for 28 days. The study is conducted at six sites, including MD Anderson Cancer Center and Yale University. The FDA has granted Fast Track designation to ATR-04 for this indication. Azitra operates as a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology.
On September 28, 2026, Azitra, Inc. entered into a sales agreement with A.G.P./Alliance Global Partners to issue and sell shares of common stock through an at-the-market offering. The company may sell up to $3,503,232 in aggregate gross proceeds subject to certain conditions. A.G.P. will receive a cash fee equal to 3.0% of the gross proceeds from sales. Azitra intends to use net proceeds for working capital and general corporate purposes. This is an equity issuance that provides potential dilution but also raises capital. The company operates in the specialty chemicals industry, specifically producing high-performance polymers.